OBJECTIVE: Natural killer (NK) cells are a lymphocyte subset that, in a hematopoietic stem cell transplantation setting, mediates a graft-vs-leukemia effect without any graft-vs-host disease. We aimed to evaluate an isolation method that can be used with Good Manufacturing Practices-grade reagents and to compare three cytokines for expansion in order to design future clinical protocols based on donor NK-cell infusions to cure relapse after allograft. MATERIALS AND METHODS: NK cells were enriched using a CD3/CD19 depletion method and expanded for 13 days in the presence of 2, 10, and 50 ng/mL interleukin (IL)-2, IL-15, or IL-7. NK-cell cytotoxicity was evaluated after isolation and culture. Expression of NKG2D, KIR2DL2, and KIR2DL1 was monitored during expansion. RESULTS: Highly T- and B-cell-depleted NK cells were obtained and enriched 2.6-fold. The optimal cytokine concentration for expansion was 10 ng/mL for IL-2 or 50 ng/mL for IL-15. NK-cell cytotoxicity was significantly improved after an overnight incubation with 10 or 50 ng/mL IL-2 or with 2, 10, or 50 ng/mL IL-15, and after 13 days with 50 ng/mL IL-15. The use of a combination of IL-2 and IL-15 showed no additional benefit and negative results were obtained with IL-7. The three NK cell receptors were significantly upregulated after culture, mainly with IL-2 or IL-15. CONCLUSION: In our study, 10 ng/mL IL-2 or 50 ng/mL IL-15 were the optimal concentrations for expansion and were equivalent in significantly enhancing cytotoxicity and modifying NK-cell receptor expression patterns. 2010 ISEH-Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: Natural killer (NK) cells are a lymphocyte subset that, in a hematopoietic stem cell transplantation setting, mediates a graft-vs-leukemia effect without any graft-vs-host disease. We aimed to evaluate an isolation method that can be used with Good Manufacturing Practices-grade reagents and to compare three cytokines for expansion in order to design future clinical protocols based on donor NK-cell infusions to cure relapse after allograft. MATERIALS AND METHODS: NK cells were enriched using a CD3/CD19 depletion method and expanded for 13 days in the presence of 2, 10, and 50 ng/mL interleukin (IL)-2, IL-15, or IL-7. NK-cell cytotoxicity was evaluated after isolation and culture. Expression of NKG2D, KIR2DL2, and KIR2DL1 was monitored during expansion. RESULTS: Highly T- and B-cell-depleted NK cells were obtained and enriched 2.6-fold. The optimal cytokine concentration for expansion was 10 ng/mL for IL-2 or 50 ng/mL for IL-15. NK-cell cytotoxicity was significantly improved after an overnight incubation with 10 or 50 ng/mL IL-2 or with 2, 10, or 50 ng/mL IL-15, and after 13 days with 50 ng/mL IL-15. The use of a combination of IL-2 and IL-15 showed no additional benefit and negative results were obtained with IL-7. The three NK cell receptors were significantly upregulated after culture, mainly with IL-2 or IL-15. CONCLUSION: In our study, 10 ng/mL IL-2 or 50 ng/mL IL-15 were the optimal concentrations for expansion and were equivalent in significantly enhancing cytotoxicity and modifying NK-cell receptor expression patterns. 2010 ISEH-Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
Authors: Yuk Pheel Park; Seung-Chul Choi; Patricia Kiesler; Aleksandra Gil-Krzewska; Francisco Borrego; Jennifer Weck; Konrad Krzewski; John E Coligan Journal: Blood Date: 2011-08-03 Impact factor: 22.113
Authors: Ana Vuletić; Irena Jovanić; Vladimir Jurišić; Zorka Milovanović; Srđan Nikolić; Igor Spurnić; Gordana Konjević Journal: Pathol Oncol Res Date: 2018-06-11 Impact factor: 3.201
Authors: Rossana Trotta; David Ciarlariello; Jessica Dal Col; Hsiaoyin Mao; Li Chen; Edward Briercheck; Jianhua Yu; Jianying Zhang; Danilo Perrotti; Michael A Caligiuri Journal: Blood Date: 2010-12-14 Impact factor: 22.113
Authors: Stacey L Berg; Mitchell S Cairo; Heidi Russell; Janet Ayello; Ashish Mark Ingle; Henry Lau; Nianhang Chen; Peter C Adamson; Susan M Blaney Journal: J Clin Oncol Date: 2010-12-13 Impact factor: 44.544
Authors: Natalia Lapteva; April G Durett; Jiali Sun; Lisa A Rollins; Leslie L Huye; Jian Fang; Varada Dandekar; Zhuyong Mei; Kimberley Jackson; Juan Vera; Jun Ando; Minhtran C Ngo; Elaine Coustan-Smith; Dario Campana; Susann Szmania; Tarun Garg; Amberly Moreno-Bost; Frits Vanrhee; Adrian P Gee; Cliona M Rooney Journal: Cytotherapy Date: 2012-08-17 Impact factor: 5.414
Authors: Shiguo Zhu; Prasad V Phatarpekar; Cecele J Denman; Vladimir V Senyukov; Srinivas S Somanchi; Hoainam T Nguyen-Jackson; Emily M Mace; Alexandra F Freeman; Stephanie S Watowich; Jordan S Orange; Steven M Holland; Dean A Lee Journal: Blood Date: 2014-06-02 Impact factor: 22.113